Making Potent CAR T Cells Using Genetic Engineering and Synergistic Agents
Immunotherapies are emerging as powerful weapons for the treatment of malignancies. Chimeric antigen receptor (CAR)-engineered T cells have shown dramatic clinical results in patients with hematological malignancies. However, it is still challenging for CAR T cell therapy to be successful in several...
Main Author: | Chi Hoon Park |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-06-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/13/3236 |
Similar Items
-
Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells
by: Michael Hiltensperger, et al.
Published: (2023-03-01) -
Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
by: Sergey Kulemzin, et al.
Published: (2021-11-01) -
Revolutionizing cancer immunotherapy in solid tumor: CAR engineering and single-cell sequencing insights
by: Zuhui Pu, et al.
Published: (2023-11-01) -
CAR-Macrophages and CAR-T Cells Synergistically Kill Tumor Cells In Vitro
by: Maoxuan Liu, et al.
Published: (2022-11-01) -
Outsmarting trogocytosis to boost CAR NK/T cell therapy
by: Faezeh Ramezani, et al.
Published: (2023-11-01)